The impact of major surgery on blood coagulation factors and thrombin generation

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 815-820

  Horne III, McDonald K ^a   Merryman, Paula K ^a   Cullinane, Ann M ^a   Nghiem, Khanh ^a   Alexander, H Richard ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; PROCOAGULANT; THROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; HUMAN; MAJOR SURGERY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL PATIENT; BIOSYNTHESIS; BLOOD CLOTTING TEST; CARCINOMA; CASE CONTROL STUDY; COMPARATIVE STUDY; HEMOSTASIS; METABOLISM; MIDDLE AGED; TIME;

ADULT; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; THROMBIN; TIME FACTORS;

EID: 35748937970     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20963     Document Type: Article

References (27)

1. Leslie SD, Toy PTCY. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol 1991;96:770-773.
2. Murray DJ, Pennell BJ, Weinstein SL, Olson JD. Packed red cells in acute blood loss: Dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995;80:336-342.
3. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360-365.
4. Hardy J-F, de Moerloose R Samama CM. The coagulopathy of massive transfusion. Vox Sang 2005;89:123-127.
5. Mann KG, Brummel K, Butenas S. What is all the thrombin for? J Thromb Haemost 2003;1:1504-1514.
6. Brummel K, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002;100:148-152.
7. Hemker HC, Dieri RA, Beguin S. Thrombin generation assays: Accruing clinical relevance. Curr Opin Hematol 2004;11:170-175.
8. Baglin T. The measurement and application of thrombin generation. Br J Haematol 2005;130:653-661.
9. Horne MK, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol 2006;133:403-408.
10. Dieri RA, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost. 2002;88:576-582.
11. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004;2:402-413.
12. Wielders S, Mukherjee M, Michiels J, et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997;77:629-636.
13. Sere KM, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: Implications for maintenance of the hemostatic balance. Blood 2004;104:3624-3630.
14. Duchemin J, Pittet J-L. Tartary M, et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994;71:331-338.
15. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-624.
16. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004;2:1954-1959.
17. Jesty J. The kinetics of inhibition of α-thrombin in human plasma. J Biol Chem 1986;261:10313-10318.
18. Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. Br J Haematol 1972;22:681-700.
19. Smith KJ, Thompson AR. Labeled factor IX kinetics in patients with hemophilia-B. Blood 1981;58:625-629.
20. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000;26:385-391.
21. Prentice CRM, Forbes CD, Smith SM. Rise of factor VIII after exercise and adrenaline infusion, measured by immunological and biochemical techniques. Thromb Res 1972;1:493-506.
22. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood 1999; 94:2169-2178.
23. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-172.
24. Fritsch P, Cvirn G, Cimenti C, et al. Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor. J Thromb Haemost 2006;4:1071-1077.
25. Von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995;86:3035-3042.
26. Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996;88:3815-3823.
27. Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994;75:521-538.